Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

Hosts explore Luna Diabetes automated insulin delivery system, designed to enhance sleep and improve glucose control for people with diabetes who use pens.

Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.

In this episode, hosts explore the findings of the Catalyst trial on hypercortisolism and its impact on type 2 diabetes.

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

In this episode, experts discuss practical guidance for screening for presymptomatic type 1 diabetes with Rifka Schulman-Rosenbaum, MD.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

In the first of 2 episodes spotlighting the meeting, hosts break down news and updates from the Advanced Technologies and Treatments for Diabetes meeting.

In this episode, hosts discuss a study assessing the benefit and feasibility of AID for type 1 diabetes with the iLet Bionic Pancreas in different settings.

In this episode, hosts discuss the launch of the Control-IQ+ AID algorithm with Laurel Messer, PhD, RN of Tandem Diabetes Care.

In this episode, hosts discuss the impact of recently launched direct, cash pay options for people using semaglutide and tirzepatide.

In this episode, hosts discuss the implications of recent changes in GLP-1 RA availability as well as diabetes technology updates.

In a recent Diabetes Dialogue segment, hosts discussed the efficacy and safety of advanced hybrid closed-loop therapy with the MiniMed 780G system.

In this Diabetes Dialogue segment, hosts discussed the strengths of trial diversity and HbA1c reductions with automated insulin delivery in type 2 diabetes.

In this episode, hosts offer perspective on recent studies assessing insulin delivery systems in adults with type 2 diabetes.

In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes.

In this episode, hosts explore the latest updates to the ADA Standards of Care on therapeutic innovations and their real-world impact on diabetes management.

In this episode, hosts explore ADA's evolving guidelines championing broader access to CGM and AID systems for personalized diabetes care.

Hosts are joined by a registered dietitian and practicing endocrinologist to discuss dietitians' role in managing patients receiving incretin therapies.

In this episode, hosts discuss optimizing insulin therapy for people with diabetes using AI-driven algorithms with Eran Atlas, CEO of DreaMed Diabetes.

In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

In this episode, hosts reflect on the advancement in CGM that reshaped care for diabetes and overall health during 2024.

To celebrate surpassing 100 episodes, Diabetes Dialogue sits down with Irl Hirsch, MD, to discuss the 25-year anniversary of continuous glucose monitoring in 2024.

In this episode, hosts discuss the collaboration between Dexcom and Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2, and Simplera CGM integration with the InPen.

In this episode, hosts break down a pair of studies from AHA 2024, BPROAD and SUMMIT, as well as a study in JAMA projecting semaglutide eligibility in US adults.

In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.

In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.